Association of serum sclerostin levels with low skeletal muscle mass: The Korean Sarcopenic Obesity Study (KSOS)

Jung A. Kim, Eun Roh, So hyeon Hong, You Bin Lee, Nam Hoon Kim, Hye-Jin Yoo, Ji A. Seo, Nan Hee Kim, Sin Gon Kim, Sei-Hyun Baik, Kyung Mook Choi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Sclerostin is an osteocyte-derived circulating protein that inhibits the Wnt/β-catenin signaling pathway. The Wnt signaling pathway plays an important role in bone and dysregulation of the Wnt signaling pathway results in insulin resistance, inflammation, and metabolic disturbance. The aim of our study was to investigate the implication of sclerostin in low muscle mass in healthy subjects. Methods: The cross-sectional study analyzed 240 healthy non-diabetic subjects from the Korean Sarcopenic Obesity Study (KSOS). Low muscle mass was defined as the sum of the appendicular skeletal muscle mass divided by the square of height (ASM/height2) as proposed by the Asian Working Group for Sarcopenia. Results: Serum sclerostin was significantly higher in the low muscle mass group than the normal muscle mass group (151.3 [79.2-187.9] vs. 74.8 [47.6-119.6] pg/mL, p = 0.001). In the partial correlation analyses adjusted for age, sex, and body mass index, ASM/height2 was negatively associated with sclerostin levels (r = −0.245, p < 0.001). Furthermore, sclerostin levels decreased linearly according to the first, second, and third tertiles of ASM/height2 even after adjusting for sex, age, body mass index, life style parameters, fasting plasma glucose, bone mineral content (BMC), and total body fat mass. Conclusions: Serum sclerostin levels were negatively correlated to skeletal muscle mass independent of confounding factors including BMC and total body fat mass.

Original languageEnglish
Article number115053
JournalBone
Volume128
DOIs
Publication statusPublished - 2019 Nov 1

Fingerprint

Wnt Signaling Pathway
Skeletal Muscle
Obesity
Muscles
Serum
Bone Density
Adipose Tissue
Body Mass Index
Sarcopenia
Osteocytes
Catenins
Insulin Resistance
Life Style
Fasting
Healthy Volunteers
Cross-Sectional Studies
Inflammation
Bone and Bones
Glucose
Proteins

Keywords

  • Bone muscle interaction
  • Low skeletal muscle mass
  • Sclerostin
  • Wnt pathway

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Physiology
  • Histology

Cite this

Association of serum sclerostin levels with low skeletal muscle mass : The Korean Sarcopenic Obesity Study (KSOS). / Kim, Jung A.; Roh, Eun; Hong, So hyeon; Lee, You Bin; Kim, Nam Hoon; Yoo, Hye-Jin; Seo, Ji A.; Kim, Nan Hee; Kim, Sin Gon; Baik, Sei-Hyun; Choi, Kyung Mook.

In: Bone, Vol. 128, 115053, 01.11.2019.

Research output: Contribution to journalArticle

Kim, Jung A. ; Roh, Eun ; Hong, So hyeon ; Lee, You Bin ; Kim, Nam Hoon ; Yoo, Hye-Jin ; Seo, Ji A. ; Kim, Nan Hee ; Kim, Sin Gon ; Baik, Sei-Hyun ; Choi, Kyung Mook. / Association of serum sclerostin levels with low skeletal muscle mass : The Korean Sarcopenic Obesity Study (KSOS). In: Bone. 2019 ; Vol. 128.
@article{ff10d57a9b084b10beeacafd10db5d3d,
title = "Association of serum sclerostin levels with low skeletal muscle mass: The Korean Sarcopenic Obesity Study (KSOS)",
abstract = "Background: Sclerostin is an osteocyte-derived circulating protein that inhibits the Wnt/β-catenin signaling pathway. The Wnt signaling pathway plays an important role in bone and dysregulation of the Wnt signaling pathway results in insulin resistance, inflammation, and metabolic disturbance. The aim of our study was to investigate the implication of sclerostin in low muscle mass in healthy subjects. Methods: The cross-sectional study analyzed 240 healthy non-diabetic subjects from the Korean Sarcopenic Obesity Study (KSOS). Low muscle mass was defined as the sum of the appendicular skeletal muscle mass divided by the square of height (ASM/height2) as proposed by the Asian Working Group for Sarcopenia. Results: Serum sclerostin was significantly higher in the low muscle mass group than the normal muscle mass group (151.3 [79.2-187.9] vs. 74.8 [47.6-119.6] pg/mL, p = 0.001). In the partial correlation analyses adjusted for age, sex, and body mass index, ASM/height2 was negatively associated with sclerostin levels (r = −0.245, p < 0.001). Furthermore, sclerostin levels decreased linearly according to the first, second, and third tertiles of ASM/height2 even after adjusting for sex, age, body mass index, life style parameters, fasting plasma glucose, bone mineral content (BMC), and total body fat mass. Conclusions: Serum sclerostin levels were negatively correlated to skeletal muscle mass independent of confounding factors including BMC and total body fat mass.",
keywords = "Bone muscle interaction, Low skeletal muscle mass, Sclerostin, Wnt pathway",
author = "Kim, {Jung A.} and Eun Roh and Hong, {So hyeon} and Lee, {You Bin} and Kim, {Nam Hoon} and Hye-Jin Yoo and Seo, {Ji A.} and Kim, {Nan Hee} and Kim, {Sin Gon} and Sei-Hyun Baik and Choi, {Kyung Mook}",
year = "2019",
month = "11",
day = "1",
doi = "10.1016/j.bone.2019.115053",
language = "English",
volume = "128",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Association of serum sclerostin levels with low skeletal muscle mass

T2 - The Korean Sarcopenic Obesity Study (KSOS)

AU - Kim, Jung A.

AU - Roh, Eun

AU - Hong, So hyeon

AU - Lee, You Bin

AU - Kim, Nam Hoon

AU - Yoo, Hye-Jin

AU - Seo, Ji A.

AU - Kim, Nan Hee

AU - Kim, Sin Gon

AU - Baik, Sei-Hyun

AU - Choi, Kyung Mook

PY - 2019/11/1

Y1 - 2019/11/1

N2 - Background: Sclerostin is an osteocyte-derived circulating protein that inhibits the Wnt/β-catenin signaling pathway. The Wnt signaling pathway plays an important role in bone and dysregulation of the Wnt signaling pathway results in insulin resistance, inflammation, and metabolic disturbance. The aim of our study was to investigate the implication of sclerostin in low muscle mass in healthy subjects. Methods: The cross-sectional study analyzed 240 healthy non-diabetic subjects from the Korean Sarcopenic Obesity Study (KSOS). Low muscle mass was defined as the sum of the appendicular skeletal muscle mass divided by the square of height (ASM/height2) as proposed by the Asian Working Group for Sarcopenia. Results: Serum sclerostin was significantly higher in the low muscle mass group than the normal muscle mass group (151.3 [79.2-187.9] vs. 74.8 [47.6-119.6] pg/mL, p = 0.001). In the partial correlation analyses adjusted for age, sex, and body mass index, ASM/height2 was negatively associated with sclerostin levels (r = −0.245, p < 0.001). Furthermore, sclerostin levels decreased linearly according to the first, second, and third tertiles of ASM/height2 even after adjusting for sex, age, body mass index, life style parameters, fasting plasma glucose, bone mineral content (BMC), and total body fat mass. Conclusions: Serum sclerostin levels were negatively correlated to skeletal muscle mass independent of confounding factors including BMC and total body fat mass.

AB - Background: Sclerostin is an osteocyte-derived circulating protein that inhibits the Wnt/β-catenin signaling pathway. The Wnt signaling pathway plays an important role in bone and dysregulation of the Wnt signaling pathway results in insulin resistance, inflammation, and metabolic disturbance. The aim of our study was to investigate the implication of sclerostin in low muscle mass in healthy subjects. Methods: The cross-sectional study analyzed 240 healthy non-diabetic subjects from the Korean Sarcopenic Obesity Study (KSOS). Low muscle mass was defined as the sum of the appendicular skeletal muscle mass divided by the square of height (ASM/height2) as proposed by the Asian Working Group for Sarcopenia. Results: Serum sclerostin was significantly higher in the low muscle mass group than the normal muscle mass group (151.3 [79.2-187.9] vs. 74.8 [47.6-119.6] pg/mL, p = 0.001). In the partial correlation analyses adjusted for age, sex, and body mass index, ASM/height2 was negatively associated with sclerostin levels (r = −0.245, p < 0.001). Furthermore, sclerostin levels decreased linearly according to the first, second, and third tertiles of ASM/height2 even after adjusting for sex, age, body mass index, life style parameters, fasting plasma glucose, bone mineral content (BMC), and total body fat mass. Conclusions: Serum sclerostin levels were negatively correlated to skeletal muscle mass independent of confounding factors including BMC and total body fat mass.

KW - Bone muscle interaction

KW - Low skeletal muscle mass

KW - Sclerostin

KW - Wnt pathway

UR - http://www.scopus.com/inward/record.url?scp=85071532579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071532579&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2019.115053

DO - 10.1016/j.bone.2019.115053

M3 - Article

AN - SCOPUS:85071532579

VL - 128

JO - Bone

JF - Bone

SN - 8756-3282

M1 - 115053

ER -